KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials-Reference-Cited by-同舟云学术

KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials

Published:2022-02 Issue:2 Volume:9 Page:e133-e142
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Kaddu-Mulindwa Dominic,Altmann Bettina,Robrecht Sandra,Ziepert Marita,Regitz Evi,Tausch Eugen,Held Gerhard,Poeschel Viola,Lesan Vadim,Bittenbring Joerg Thomas,Thurner Lorenz,Pfreundschuh Michael,Christofyllakis Konstantinos,Truemper Lorenz,Loeffler Markus,Schmitz Norbert,Hoth Markus,Hallek Michael,Fischer Kirsten,Stilgenbauer Stephan,Bewarder Moritz,Rixecker Torben Millard

Publisher

Elsevier BV

Subject

Hematology

Reference30 articles.

1. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

3. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

4. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{γ}RIIIa-158 V/V and V/F polymorphism;Hatjiharissi;Blood,2007

5. In search of the ‘missing self’: MHC molecules and NK cell recognition;Ljunggren;Immunol Today,1990

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017–2023);Frontiers in Pharmacology;2024-08-21

2. Killer instincts: natural killer cells as multifactorial cancer immunotherapy;Frontiers in Immunology;2023-11-28

3. “HLA-C: evolution, epigenetics, and pathological implications in the major histocompatibility complex”;Frontiers in Genetics;2023-07-03

4. The impact of killer cell immunoglobulin-like receptor (KIR) genes and human leukocyte antigen (HLA) class I ligands on predisposition or protection against prostate cancer;Immunobiology;2023-03

5. Genome-Wide Association Study in Acute Tubulointerstitial Nephritis;Journal of the American Society of Nephrology;2023-02-02